FUT9

FUT9 is an α1,3-fucosyltransferase of the GT10 family that synthesizes Lewis X (and Lewis Y) antigens by transferring fucose onto the GlcNAc of terminal N-acetyllactosamine on both glycoproteins and glycolipids (PMID:12626397, PMID:37202521). Crystal structures of FUT9 captured with GDP, acceptor glycans, and a Michaelis complex, together with active-site mutagenesis and kinetics, define its substrate specificity determinants and an inverting catalytic mechanism, and the enzyme is distinguished from paralogs FUT4/FUT6 by its cation independence (PMID:10386598, PMID:37202521). FUT9 is the dominant Lewis X-synthesizing enzyme in brain, with >10-fold higher activity on oligosaccharides and >100-fold higher activity on glycolipid acceptors than FUT4 (PMID:12626397), and is the sole enzyme generating SSEA-1 (Lewis X) in mouse embryos and primordial germ cells in vivo, where its loss is nonetheless compatible with normal development and fertility (PMID:15121843). It carries out widespread, rather than protein-restricted, Lewis X modification of N-glycans in vivo (PMID:26244810), contributes to human leukocyte E-selectin ligand biosynthesis (PMID:23192350), and is required for normal deep-layer cortical and retinal neuron development (PMID:35753011). Beyond glycan synthesis, FUT9 activity promotes a cancer stem cell-like phenotype in colorectal and esophageal cancer through stemness markers including CD44, OCT4, and Sox2 (PMID:29196508, PMID:32927726), and is transcriptionally activated by ELF4 (PMID:37674363) and suppressed by hsa-miR-1246 acting through GSK3β (PMID:39931532).

1. 1999 Medium

   Establishing that human FUT9 is an α1,3-fucosyltransferase distinct from its paralogs answered whether it represented a separate catalytic activity, with cation independence as its defining biochemical signature.

   Evidence Molecular cloning and in vitro enzymatic assays with cation supplementation

   PMID:10386598

   Open questions at the time

   • No structural or mutagenesis basis for cation independence at this stage
   • Physiological acceptor and tissue context not addressed
2. 2000 Medium

   Acceptor specificity profiling sharpened how FUT9 differs functionally from FUT4, showing it shares Lewis X-type activity but cannot efficiently use lac-di-NAc acceptors.

   Evidence cDNA cloning from embryonic libraries with in vitro substrate specificity, kinetics, and inhibitor assays; orthologous comparison on oligosaccharide vs lipid acceptors in rat

   PMID:10929005 PMID:11020213

   Open questions at the time

   • In vivo relevance of the lipid-acceptor preference not yet tested
   • No knockout to confirm enzyme is rate-limiting
3. 2003 High

   Combining recombinant kinetics with tissue mRNA and activity profiling resolved which enzyme produces brain Lewis X, identifying FUT9 as dominant over FUT4 by >10-fold on glycans and >100-fold on glycolipids.

   Evidence Recombinant enzyme assays, RT-PCR quantification, and brain homogenate activity profiling

   PMID:12626397

   Open questions at the time

   • Causal requirement in brain not yet shown by genetic loss
   • Specific glycolipid/glycoprotein targets in brain not enumerated
4. 2004 High

   Genetic knockout established FUT9 as the sole enzyme generating SSEA-1 in vivo and, unexpectedly, that this antigen is dispensable for embryogenesis and fertility.

   Evidence Fut9-/- mice with immunohistochemistry of SSEA-1 and developmental/fertility phenotyping

   PMID:15121843

   Open questions at the time

   • Functional role of Lewis X if any not revealed by overt phenotype
   • Compensation by other enzymes not formally excluded
5. 2012 High

   Loss- and gain-of-function in human cells defined FUT9's contribution to E-selectin ligand synthesis in leukocytes and revealed a human-specific role not shared by mouse.

   Evidence shRNA knockdown in HL-60, overexpression in HEK293T, and selectin rolling adhesion assays under shear

   PMID:23192350

   Open questions at the time

   • Identity of the FUT9-fucosylated selectin ligand proteins not defined
   • Basis of the human/mouse species difference unresolved
6. 2013 Medium

   Identification and validation of androgen receptor binding sites placed Fut9 expression under hormonal control in a tissue-specific manner in the male reproductive tract.

   Evidence Mouse castration model, RT-PCR, ARBS identification, and luciferase reporter assays

   PMID:24284406

   Open questions at the time

   • Downstream glycan/physiological consequence in epididymis not shown
   • Single lab without independent confirmation
7. 2015 High

   Comparative glycoproteomics established that Fut9 carries out widespread, not protein-selective, Lewis X modification of N-glycans in vivo.

   Evidence AAL affinity enrichment and site-specific MS N-glycomics of wild-type vs Fut9 knockout kidney

   PMID:26244810

   Open questions at the time

   • Functional consequence of kidney Lewis X loss not assessed
   • Restricted to one tissue
8. 2020 Medium

   Reciprocal gain- and loss-of-function across colorectal cancer models connected FUT9 enzymatic activity to a cancer stem cell-like state via stemness markers and chemoresistance.

   Evidence De novo FUT9 expression and knockout in CRC lines, tumorsphere and 5-FU resistance assays, xenografts, RNA-seq regulon analysis, and marker readouts (CD44, OCT4, Sox2, ALDH)

   PMID:29196508 PMID:32927726

   Open questions at the time

   • Glycan target(s) mediating the stemness effect not identified
   • Mechanistic link between fucosylation and transcriptional stemness networks unresolved
9. 2023 High

   Multiple substrate-complex crystal structures plus mutagenesis defined the catalytic mechanism and substrate specificity determinants of FUT9 and framed modular evolution within the GT10 family.

   Evidence X-ray crystallography of GDP/acceptor/Michaelis complexes with active-site mutagenesis and kinetics

   PMID:37202521

   Open questions at the time

   • Structural basis of substrate handoff on glycolipid vs glycoprotein acceptors not fully resolved
   • No structure with full lipid-linked acceptor
10. 2024 Medium

    ChIP and functional experiments identified ELF4 as a direct transcriptional activator of FUT9, placing the enzyme downstream of a defined oncogenic transcription factor in esophageal cancer stemness.

    Evidence RNA-seq, ChIP at the FUT9 locus, and rescue/knockdown functional assays in ESCC cells with in vivo readouts

    PMID:37674363

    Open questions at the time

    • Direct binding shown but quantitative promoter elements not mapped
    • Single lab
11. 2025 Medium

    Dual-luciferase validation established hsa-miR-1246 as a direct repressor of FUT9 via its 3' UTR, linking FUT9 to GSK3β signaling in NSCLC.

    Evidence Dual-luciferase 3' UTR reporter, miRNA mimic/inhibitor assays, and GSK3β Western blotting

    PMID:39931532

    Open questions at the time

    • Mechanistic chain from FUT9 fucosylation to GSK3β phosphorylation not resolved
    • Single lab

• It remains unresolved which specific FUT9-fucosylated glycoprotein or glycolipid substrates mediate its roles in neuronal development, E-selectin ligand function, and cancer stemness.
• Causal glycan targets for each phenotype unidentified
• Mechanism connecting glycan synthesis to transcriptional stemness networks unknown